Event JSON
{
"id": "f35452ba2f1a1b8ee8197d3f6474a1df879d1d1827e4b87490d93e66c65042fd",
"pubkey": "9d3345095e986ded9af724d26a8c5bee050bfd615c32fc5e76981a089c72008e",
"created_at": 1744585604,
"kind": 1,
"tags": [
[
"r",
"https://www.theguardian.com/society/2025/apr/14/melanoma-patients-in-england-get-fast-track-access-to-cancer-vaccine"
],
[
"subject",
"Melanoma patients in England get fast-track access to cancer vaccine"
],
[
"published_at",
"1744585227"
],
[
"image",
"https://i.guim.co.uk/img/media/40335aff708b566272e43ee09d22b8bef85fe0d6/0_160_4832_2901/master/4832.jpg?width=140\u0026quality=85\u0026auto=format\u0026fit=max\u0026s=31eedd78c09edc263a0ca1e0e46c4a41"
],
[
"p",
"9d3345095e986ded9af724d26a8c5bee050bfd615c32fc5e76981a089c72008e",
"wss://relay-testnet.k8s.layer3.news"
],
[
"imeta",
"url https://i.guim.co.uk/img/media/40335aff708b566272e43ee09d22b8bef85fe0d6/0_160_4832_2901/master/4832.jpg?width=140\u0026quality=85\u0026auto=format\u0026fit=max\u0026s=31eedd78c09edc263a0ca1e0e46c4a41"
],
[
"t",
"liberal:perspective"
],
[
"summary",
"The vaccine, developed by Scancell, is part of the NHS England's Cancer Vaccine Launch Pad program, which aims to provide 10,000 patients with personalized cancer treatments by 2030. The trial will be conducted at seven hospitals across the country, and patients with advanced skin melanoma will be given fast-track access. The vaccine has the potential to revolutionize cancer care and save lives."
]
],
"content": "nostr:nprofile1qy3hwumn8ghj7un9d3shjtt5v4ehgmn9wshxkwrn9ekxz7t9wgejumn9waesqgyaxdzsjh5cdhke4aey6f4gcklwq59l6c2uxt79ua5crgyfcusq3cwyf5fq\nhttps://i.guim.co.uk/img/media/40335aff708b566272e43ee09d22b8bef85fe0d6/0_160_4832_2901/master/4832.jpg?width=140\u0026quality=85\u0026auto=format\u0026fit=max\u0026s=31eedd78c09edc263a0ca1e0e46c4a41\nNHS Cancer Vaccine Launch Pad expanded to include trial for patients with advanced type of skin cancerPatients with an advanced type of skin melanoma in England will be given fast-track access to a “revolutionary” new cancer vaccine as part of an NHS trial.The vaccine, known as iSCIB1+ (ImmunoBody), helps the immune system recognise cancer cells and therefore better respond to immunotherapy treatment. Continue reading...\nhttps://www.theguardian.com/society/2025/apr/14/melanoma-patients-in-england-get-fast-track-access-to-cancer-vaccine",
"sig": "1bfddb5135befdbf7f9d69602aa66a15aef5a7115b1be886f93d2f5171cbe52bc1131eb5c9700e33a6004b7ad5eff5d2eabd0edde8da9099b085ac121704c920"
}
